دورية أكاديمية
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy
| العنوان: | Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy |
|---|---|
| المؤلفون: | Fanotto, Valentina, Uccello, Mario, Pecora, Irene, Rimassa, Lorenza, Leone, Francesco, Rosati, Gerardo, Santini, Daniele, Giampieri, Riccardo, Di Donato, Samantha, Tomasello, Gianluca, Silvestris, Nicola, Pietrantonio, Filippo, Battaglin, Francesca, Avallone, Antonio, Scartozzi, Mario, Lutrino, Eufemia Stefania, Melisi, Davide, Antonuzzo, Lorenzo, Pellegrino, Antonio, Ferrari, Laura, Bordonaro, Roberto, Vivaldi, Caterina, Gerratana, Lorenzo, Bozzarelli, Silvia, Filippi, Roberto, Bilancia, Domenico, Russano, Marco, Aprile, Giuseppe |
| المساهمون: | V. Fanotto, M. Uccello, I. Pecora, L. Rimassa, F. Leone, G. Rosati, D. Santini, R. Giampieri, S. Di Donato, G. Tomasello, N. Silvestri, F. Pietrantonio, F. Battaglin, A. Avallone, M. Scartozzi, E.S. Lutrino, D. Melisi, L. Antonuzzo, A. Pellegrino, L. Ferrari, R. Bordonaro, C. Vivaldi, L. Gerratana, S. Bozzarelli, R. Filippi, D. Bilancia, M. Russano, G. Aprile |
| بيانات النشر: | AlphaMed press |
| سنة النشر: | 2017 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | advanced gastric cancer, overall survival, prognostic factor, progression-free survival, third-line chemotherapy, oncology, cancer research, Settore MED/06 - Oncologia Medica |
| الوصف: | Background. Second-line therapy has consistently demonstrated survival benefit if compared with best supportive care; however, there is limited evidence whether further lines of treatment may improve the prognosis of advanced gastric cancer (AGC) patients. Materials and Methods. Starting from a real-world cohort of 868 AGC patients, we retrospectively analyzed baseline parameters, tumor characteristics, and treatment data of those treated with at least three lines. Categorical features were described through cross-tables and chi-square test. We explored the impact of treatment intensity and progression-free survival (PFS) experienced in previous lines on PFS and overall survival in third-line by uni- and multivariate Cox regression models and described by Kaplan-Meier estimator plot with log-rank test. Results. Overall, 300 patients were included in the analysis. The most common site of primary tumor was gastric body; 45.3% of cancers had an intestinal histotype, 14% were human epidermal growth receptor 2 positive. In third-line, 45.7% of patients received a single-agent chemotherapy, 49.7% a combination regimen. Patients who had experienced a first-line PFS ≥6.9 months had a better prognosis compared with those who had achieved a shorter one. Consistently, a second-line PFS ≥3.5 months positively influenced the prognosis. Patients receiving a third-line combination regimen had better outcomes compared with those treated with a single-agent chemotherapy. Conclusion. Our real-world study confirms that selected AGC patients may receive third-line treatment. Longer PFS in previous lines or a more intense third-line treatment positively influenced prognosis. Further efforts are warranted to define the best therapeutic sequences, and to identify the optimal candidate for treatment beyond second-line. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/28860412; info:eu-repo/semantics/altIdentifier/wos/WOS:000417923100010; volume:22; issue:12; firstpage:1463; lastpage:1469; numberofpages:7; journal:THE ONCOLOGIST; http://hdl.handle.net/2434/564004Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85038581397 |
| DOI: | 10.1634/theoncologist.2017-0158 |
| الإتاحة: | https://doi.org/10.1634/theoncologist.2017-0158Test http://hdl.handle.net/2434/564004Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.42309221 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1634/theoncologist.2017-0158 |
|---|